Survey on the current gynaecological approach of ovarian cancer patients: The utility of HIPEC.
hyperthermic intraperitoneal chemotherapy (HIPEC)
ovarian cancer
survey
Journal
Pleura and peritoneum
ISSN: 2364-768X
Titre abrégé: Pleura Peritoneum
Pays: Germany
ID NLM: 101710063
Informations de publication
Date de publication:
01 Mar 2020
01 Mar 2020
Historique:
received:
10
11
2019
accepted:
17
12
2019
entrez:
22
8
2020
pubmed:
22
8
2020
medline:
22
8
2020
Statut:
epublish
Résumé
The aim of this survey was to acquire an overview of the current management of ovarian cancer with an emphasis on the utility of hyperthermic intraperitoneal chemotherapy (HIPEC). In total, 467 Medical Oncologists, Surgical Oncologists or Gynaecologic Oncologists were participated and answered to this survey. The resectability of disease was evaluated by laparoscopy from 48.5% of the participants, while 51.5% answered that they stage their patients pre-surgically with the use of CT or MRI. The preferred first intervention in advanced ovarian cancer patients is the neoadjuvant chemotherapy followed by interval cytoreductive surgery (72%). Regarding the use of HIPEC, almost half of the participants answered that there is role of HIPEC use in ovarian cancer patients undergoing interval debulking surgery, while almost 70% answered positively about the utility of HIPEC use in ovarian cancer recurrence. As for the role of lymphadenectomy in advanced ovarian cancer patients, half of the responders answered negatively. Finally, only 25% of the participants responded that they always check the The results of this survey indicate the utility of HIPEC in treatment of ovarian cancer patients and the differences in the overall management of ovarian cancer patients in the current clinical practice.
Sections du résumé
BACKGROUND
BACKGROUND
The aim of this survey was to acquire an overview of the current management of ovarian cancer with an emphasis on the utility of hyperthermic intraperitoneal chemotherapy (HIPEC).
RESULTS
RESULTS
In total, 467 Medical Oncologists, Surgical Oncologists or Gynaecologic Oncologists were participated and answered to this survey. The resectability of disease was evaluated by laparoscopy from 48.5% of the participants, while 51.5% answered that they stage their patients pre-surgically with the use of CT or MRI. The preferred first intervention in advanced ovarian cancer patients is the neoadjuvant chemotherapy followed by interval cytoreductive surgery (72%). Regarding the use of HIPEC, almost half of the participants answered that there is role of HIPEC use in ovarian cancer patients undergoing interval debulking surgery, while almost 70% answered positively about the utility of HIPEC use in ovarian cancer recurrence. As for the role of lymphadenectomy in advanced ovarian cancer patients, half of the responders answered negatively. Finally, only 25% of the participants responded that they always check the
CONCLUSIONS
CONCLUSIONS
The results of this survey indicate the utility of HIPEC in treatment of ovarian cancer patients and the differences in the overall management of ovarian cancer patients in the current clinical practice.
Identifiants
pubmed: 32821775
doi: 10.1515/pp-2019-0029
pii: pp-pp-2019-0029
pmc: PMC7410114
doi:
Types de publication
Journal Article
Langues
eng
Pagination
20190029Informations de copyright
© 2020 Iavazzo et al., published by De Gruyter.
Déclaration de conflit d'intérêts
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
Références
Gynecol Oncol. 2007 Jun;105(3):604-8
pubmed: 17321572
Ann Surg Oncol. 2015 May;22(5):1570-5
pubmed: 25391263
Eur J Surg Oncol. 2019 Mar;45(3):301-309
pubmed: 30786961
Gynecol Oncol. 2011 Aug;122(2):221-5
pubmed: 21543112
J Natl Cancer Inst. 2005 Apr 20;97(8):560-6
pubmed: 15840878
Lancet Oncol. 2018 Dec;19(12):1680-1687
pubmed: 30413383
Int J Hyperthermia. 2017 Aug;33(5):548-553
pubmed: 28092994
Int J Gynecol Cancer. 2019 Oct;29(8):1327-1331
pubmed: 31420412
N Engl J Med. 2012 Apr 12;366(15):1382-92
pubmed: 22452356
Expert Rev Anticancer Ther. 2017 Dec;17(12):1147-1158
pubmed: 29086618
N Engl J Med. 2019 Feb 28;380(9):822-832
pubmed: 30811909
Arch Gynecol Obstet. 2018 Oct;298(4):673-674
pubmed: 30145687
N Engl J Med. 2018 Dec 27;379(26):2495-2505
pubmed: 30345884
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
N Engl J Med. 2010 Sep 2;363(10):943-53
pubmed: 20818904
Eur J Surg Oncol. 2015 Dec;41(12):1578-89
pubmed: 26453145
Oncotarget. 2017 Jun 6;8(23):37807-37816
pubmed: 27906676
N Engl J Med. 2018 Jan 18;378(3):230-240
pubmed: 29342393
Gynecol Oncol. 2019 Feb;152(2):416-425
pubmed: 30409489
Cancer. 2009 Sep 15;115(18):4118-26
pubmed: 19670446
Int J Gynecol Cancer. 2012 Mar;22(3):407-16
pubmed: 22367320
Gynecol Oncol. 2017 Oct;147(1):61-65
pubmed: 28779965
J Gynecol Oncol. 2019 Jan;30(1):e3
pubmed: 30479087
Curr Probl Cancer. 2019 Apr;43(2):151-159
pubmed: 30149960